Compare Stocks: CELZ, SGMO, LTRN, and BYSI

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BYSI BeyondSpring	$0.72	$1.28	$0.67 ▼ $2.44	$29.61M	0.48	2.05 million shs	59,151 shs
CELZ Creative Medical Technology	$1.31 +2.3%	$1.20	$0.62 ▼ $6.25	$8.44M	1.94	20.15 million shs	544,953 shs
LTRN Lantern Pharma	$2.34 +2.2%	$3.17	$1.11 ▼ $4.70	$29.28M	2.34	89,104 shs	184,571 shs
SGMO Sangamo Therapeutics	$0.07	$0.09	$0.06 ▼ $0.77	$30.66M	1.3	8.10 million shs	N/A

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BYSI BeyondSpring	0.00%	-14.18%	-36.27%	-54.13%	-58.13%
CELZ Creative Medical Technology	+2.34%	+7.38%	+55.73%	-45.19%	-57.05%
LTRN Lantern Pharma	+2.18%	-11.70%	-17.61%	-33.14%	-47.65%
SGMO Sangamo Therapeutics	0.00%	0.00%	0.00%	-57.54%	-86.30%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BYSI BeyondSpring	$0.72	$1.28	$0.67 ▼ $2.44	$29.61M	0.48	2.05 million shs	59,151 shs
CELZ Creative Medical Technology	$1.31 +2.3%	$1.20	$0.62 ▼ $6.25	$8.44M	1.94	20.15 million shs	544,953 shs
LTRN Lantern Pharma	$2.34 +2.2%	$3.17	$1.11 ▼ $4.70	$29.28M	2.34	89,104 shs	184,571 shs
SGMO Sangamo Therapeutics	$0.07	$0.09	$0.06 ▼ $0.77	$30.66M	1.3	8.10 million shs	N/A

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BYSI BeyondSpring	0.00%	-14.18%	-36.27%	-54.13%	-58.13%
CELZ Creative Medical Technology	+2.34%	+7.38%	+55.73%	-45.19%	-57.05%
LTRN Lantern Pharma	+2.18%	-11.70%	-17.61%	-33.14%	-47.65%
SGMO Sangamo Therapeutics	0.00%	0.00%	0.00%	-57.54%	-86.30%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BYSI BeyondSpring	1.00	Sell	N/A	N/A
CELZ Creative Medical Technology	2.00	Hold	N/A	N/A
LTRN Lantern Pharma	1.00	Sell	N/A	N/A
SGMO Sangamo Therapeutics	1.75	Reduce	$5.50	7,332.43% Upside

Current Analyst Ratings Breakdown

Latest CELZ, SGMO, LTRN, and BYSI Analyst Ratings

Date	Company	Brokerage	Action	Rating
8/20/2026	CELZ Creative Medical Technology	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/13/2026	CELZ Creative Medical Technology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/31/2026	CELZ Creative Medical Technology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/29/2026	LTRN Lantern Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/14/2026	LTRN Lantern Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/8/2026	BYSI BeyondSpring	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/29/2026	LTRN Lantern Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
5/22/2026	CELZ Creative Medical Technology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
5/22/2026	LTRN Lantern Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 8/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BYSI BeyondSpring	$1.75M	16.92	$0.11 per share	6.34	($0.88) per share	-0.82
CELZ Creative Medical Technology	$10K	863.29	N/A	N/A	$1.32 per share	0.99
LTRN Lantern Pharma	N/A	N/A	N/A	N/A	($0.25) per share	N/A
SGMO Sangamo Therapeutics	$39.55M	0.78	N/A	N/A	($0.04) per share	-1.85

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BYSI BeyondSpring	-$1.01M	-$0.12	N/A	N/A	N/A	N/A	N/A	-28.88%	N/A
CELZ Creative Medical Technology	-$5.99M	-$2.07	N/A	N/A	N/A	N/A	-86.52%	-81.96%	11/6/2026 (Estimated)
LTRN Lantern Pharma	-$17.12M	-$1.62	N/A	N/A	N/A	N/A	-368.02%	-148.62%	N/A
SGMO Sangamo Therapeutics	-$122.93M	-$0.38	N/A	N/A	N/A	-310.81%	-2,662.06%	-132.12%	N/A

Latest CELZ, SGMO, LTRN, and BYSI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	BYSI BeyondSpring	-$0.54	-$0.02	+$0.52	-$0.02	$8.77 million	N/A
8/14/2026	Q2 2026	LTRN Lantern Pharma	-$0.38	-$0.57	-$0.19	-$0.57	N/A	N/A
8/7/2026	Q2 2026	CELZ Creative Medical Technology	-$0.39	-$0.41	-$0.02	-$0.41	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BYSI BeyondSpring	N/A	N/A	N/A	N/A	N/A
CELZ Creative Medical Technology	N/A	N/A	N/A	N/A	N/A
LTRN Lantern Pharma	N/A	N/A	N/A	N/A	N/A
SGMO Sangamo Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BYSI BeyondSpring	N/A	0.70	1.09
CELZ Creative Medical Technology	N/A	12.90	12.90
LTRN Lantern Pharma	N/A	1.96	1.87
SGMO Sangamo Therapeutics	N/A	0.84	0.84

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BYSI BeyondSpring	40.29%
CELZ Creative Medical Technology	1.42%
LTRN Lantern Pharma	28.62%
SGMO Sangamo Therapeutics	56.92%

Insider Ownership

Company	Insider Ownership
BYSI BeyondSpring	29.31%
CELZ Creative Medical Technology	1.00%
LTRN Lantern Pharma	8.50%
SGMO Sangamo Therapeutics	4.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BYSI BeyondSpring	80	41.12 million	29.07 million	Optionable
CELZ Creative Medical Technology	5	6.59 million	6.53 million	Not Optionable
LTRN Lantern Pharma	20	12.78 million	11.70 million	Optionable
SGMO Sangamo Therapeutics	480	414.29 million	397.29 million	Optionable

CELZ, SGMO, LTRN, and BYSI Headlines

Recent News About These Companies

Sangamo Therapeutics Advances Bankruptcy Asset Sale Process

July 20, 2026 | tipranks.com

Sangamo Therapeutics Inc SGMO

July 7, 2026 | morningstar.comM

Sangamo Therapeutics Enters Into Asset Sale Agreements with Lilly and Astellas

June 24, 2026 | markets.businessinsider.com

Sangamo falls after Chapter 11 bankruptcy filing; Eli Lilly and Astellas to acquire key assets

June 24, 2026 | seekingalpha.com

Sangamo Therapeutics files for Chapter 11 bankruptcy

June 24, 2026 | msn.com

Sangamo Therapeutics Initiates Chapter 11 and Asset Sales

June 23, 2026 | tipranks.com

Sangamo Therapeutics Announces Exploration of Strategic Alternatives to Maximize Value for Stakeholders

June 8, 2026 | globenewswire.com

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q1 2026 Earnings Call Transcript

May 16, 2026 | insidermonkey.com

Sangamo Therapeutics Inc (SGMO) Q1 2026 Earnings Call Highlights: Progress Amidst Financial ...

May 16, 2026 | finance.yahoo.com

Sangamo Therapeutics Reports No Unregistered Equity Sales or Share Repurchases for the Period

May 16, 2026 | tipranks.com

Sangamo Therapeutics, Inc. (SGMO) Q1 2026 Earnings Call Transcript

May 14, 2026 | seekingalpha.com

Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates

May 14, 2026 | zacks.com

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2026 Financial Results

May 14, 2026 | globenewswire.com

Sangamo Therapeutics Announces First Quarter 2026 Earnings Call

May 11, 2026 | markets.businessinsider.com

Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Transition to Trading on OTCQB Venture Market

May 5, 2026 | finanznachrichten.de

Sangamo Therapeutics to Present Pipeline and Technology Advances at the 29th Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT)

April 30, 2026 | globenewswire.com

Sangamo Therapeutics (SGMO) Nasdaq delisting shifts stock to OTCQB market

April 29, 2026 | finance.yahoo.com

Sangamo Therapeutics Announces Transition to Trading on OTCQB Venture Market

April 29, 2026 | globenewswire.com

Sangamo Therapeutics (NASDAQ:SGMO) Insider Sells $17,456.75 in Stock

April 24, 2026 | insidertrades.com

Sangamo Therapeutics Faces Rising Trade Policy Risks, Higher Costs and Global Growth Uncertainty

April 1, 2026 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CELZ, SGMO, LTRN, and BYSI Company Descriptions

BeyondSpring NASDAQ:BYSI

$0.72 0.00 (0.00%)

As of 08/21/2026 04:00 PM Eastern

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.

Creative Medical Technology NASDAQ:CELZ

$1.31 +0.03 (+2.34%)

As of 08/21/2026 04:00 PM Eastern

Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.

Lantern Pharma NASDAQ:LTRN

$2.34 +0.05 (+2.18%)

As of 08/21/2026 04:00 PM Eastern

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

Sangamo Therapeutics NASDAQ:SGMO

$0.07 0.00 (0.00%)

As of 08/21/2026

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CELZ, SGMO, LTRN, and BYSI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CELZ, SGMO, LTRN, and BYSI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CELZ, SGMO, LTRN, and BYSI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CELZ, SGMO, LTRN, and BYSI Company Descriptions

BeyondSpring NASDAQ:BYSI

Creative Medical Technology NASDAQ:CELZ

Lantern Pharma NASDAQ:LTRN

Sangamo Therapeutics NASDAQ:SGMO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CELZ, SGMO, LTRN, and BYSI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CELZ, SGMO, LTRN, and BYSI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CELZ, SGMO, LTRN, and BYSI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CELZ, SGMO, LTRN, and BYSI Company Descriptions

BeyondSpring NASDAQ:BYSI

Creative Medical Technology NASDAQ:CELZ

Lantern Pharma NASDAQ:LTRN

Sangamo Therapeutics NASDAQ:SGMO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools